WEKO3
アイテム
Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer
https://asahikawa-med.repo.nii.ac.jp/records/4257
https://asahikawa-med.repo.nii.ac.jp/records/425714b47a6e-008f-41e5-8e6c-614f94998825
名前 / ファイル | ライセンス | アクション |
---|---|---|
![]() |
|
Item type | 学術雑誌論文 / Journal Article_02(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-01-25 | |||||
タイトル | ||||||
タイトル | Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer | |||||
言語 | en | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
林, 諭史
× 林, 諭史× Kumai, T× Matsuda, Y× Aoki, N× Sato, K× Kimura, S× Kitada, M× Tateno, M× Celis, E× Kobayashi, H |
|||||
書誌情報 |
Journal of translational medicine 巻 5, 号 9, p. 191, 発行日 2011-11-01 |
|||||
ISSN | ||||||
収録物識別子タイプ | PISSN | |||||
収録物識別子 | 1479-5876 | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1186/1479-5876-9-191 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 22053850 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background T-cell based immunotherapy for lung cancer (LC) could be a promising and novel therapeutic approach. Six-transmembrane epithelial antigen of the prostate (STEAP) and the polycomb group protein enhancer of zeste homolog 2 (EZH2) are highly expressed in LC and since the expression of molecules in normal tissue is significantly lower as compared to tumor cells, these proteins are considered as potential tumor-associated antigens (TAAs) for developing T-cell based immunotherapy. \nMethods We assessed the capacity of predicted CD4 T-cell epitopes from STEAP and EZH2 to induce anti-tumor immune responses to LC cell lines. \nResults Out of several predicted epitopes, two synthetic peptides, STEAP281-296 and EZH295-109, were effective in inducing CD4 T-cell responses that were restricted by HLA-DR1, DR15, or DR53 molecules, indicating that the peptides function as promiscuous T-cell epitopes. Moreover, STEAP281-296 and EZH295-109-reactive T-cells could directly recognize STEAP or EZH2 expressing LC cells in an HLA-DR restricted manner. In addition, some STEAP-reactive T-cells responded to STEAP+ tumor cell lysates presented by autologous dendric cells. Most significantly, both of these peptides were capable of stimulating in vitro T-cell responses in patients with LC. \nConclusions Peptides STEAP281-296 and EZH295-109 function as strong CD4 T-cell epitopes that can elicit effective anti-tumor T-cell responses against STEAP or EZH2 expressing LC. These observations may facilitate the translation of T-cell based immunotherapy into the clinic for the treatment of LC. | |||||
言語 | en | |||||
注記 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Publisher | |||||
資源タイプ | ||||||
内容記述タイプ | Other | |||||
内容記述 | text | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
フォーマット | ||||||
内容記述タイプ | Other | |||||
内容記述 | application/pdf | |||||
ID(XooNIps) | ||||||
値 | 22053850 | |||||
閲覧数(XooNIps) | ||||||
値 | 717 | |||||
ダウンロード数(XooNIps) | ||||||
値 | 321 |